{"disease":{"id":"tumor-of-breast","name":"tumor of breast"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05364450","title":"Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":390,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT02894398","title":"Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":388,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT02632448","title":"A Study of LY2880070 in Participants With Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Esperas Pharma Inc.","has_results":false},{"nct_id":"NCT01177397","title":"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT01219699","title":"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03809988","title":"PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT01881230","title":"Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT02187991","title":"Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"US Oncology Research","has_results":true},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT05584644","title":"A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03589339","title":"NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"Nanobiotix","has_results":false},{"nct_id":"NCT03606616","title":"Prospective Feasibility Study Applying the ACOSOG Z0011 Criteria to Chinese Patients","phase":"","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT02565758","title":"ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT04348916","title":"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Oncorus, Inc.","has_results":false},{"nct_id":"NCT03007979","title":"Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02891681","title":"Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT05133674","title":"Therapeutic Dose Monitoring (TDM) of Tamoxifen","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT06253195","title":"BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT03449108","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06264921","title":"A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05727813","title":"To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT06471673","title":"A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"BriaCell Therapeutics Corporation","has_results":false},{"nct_id":"NCT04091295","title":"BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Aveni Foundation","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}